|
FY2010
12 months to Dec 31, 2010
|
FY2009
12 months to Dec 31, 2009
|
|
|---|---|---|
| Cash Flows from Operating Activities: | ||
| Net income | ||
| Reconciliation of net income to cash flows from operating activities: | ||
| Depreciation and amortization | ||
| Stock-based compensation | ||
| Provision for bad debts | ||
| Purchase of in-process research and development | ||
| Charge for impaired assets | ||
| Gain on sale of business | ||
| Gain on acquisition of business | ||
| Acquisition From Bayer | ||
| Total gain on acquisition of business | ||
| Goodwill | ||
| Liabilities for exit activities and integration | ||
| Income taxes payable | ||
| Net deferred tax assets (liabilities) | ||
| Net liabilities assumed | ||
| Contingent consideration expense | ||
| Losses on investments in equity securities, net | ||
| Equity in (income) loss on equity method investments | ||
| Deferred income tax benefit | ||
| Tax benefit from employee stock-based compensation | ||
| Excess tax benefit from stock-based compensation | ||
| Other | ||
| Increase (decrease) in cash from working capital changes (excluding impact of acquired assets and assumed liabilities): | ||
| Accounts receivable | ||
| Inventories | ||
| Other current assets | ||
| Accounts payable, accrued expenses and deferred revenue | ||
| Cash flows from operating activities | ||
| Cash Flows from Investing Activities: | ||
| Purchases of investments | ||
| Sales and maturities of investments | ||
| Purchases of equity securities | ||
| Proceeds from sales of investments in equity securities | ||
| Proceeds from sale of business | ||
| Purchases of property, plant and equipment | ||
| Acquisition From Bayer | ||
| Total purchases of property, plant and equipment | ||
| (Investments in) distributions from equity method investment | ||
| Acquisitions | ||
| Payment of note receivable from Dyax | ||
| Purchases of other intangible assets | ||
| Other | ||
| Cash flows from investing activities | ||
| Cash Flows from Financing Activities: | ||
| Proceeds from issuance of common stock | ||
| Repurchases of our common stock | ||
| Excess tax benefit from stock-based compensation | ||
| Proceeds from issuance of debt, net | ||
| Payments of debt and capital lease obligations | ||
| Increase (decrease) in bank overdrafts | ||
| Payment of contingent consideration obligation | ||
| Other | ||
| Cash flows from financing activities | ||
| Effect of exchange rate changes on cash | ||
| Increase (decrease) in cash and cash equivalents | ||
| Cash and cash equivalents at beginning of period | ||
| Less: Cash included in assets held for sale | ||
| Cash and cash equivalents at end of period | ||
| Supplemental disclosures of cash flows: | ||
| Cash paid during the year for: | ||
| Interest, net of capitalized interest | ||
| Income taxes | ||
| Net cash paid for acquisitions and acquisition costs | ||
| Acquisition From Bayer | ||
| Total net cash paid for acquisitions and acquisition costs | ||
| In conjunction with acquisitions, we assumed the following net liabilities: | ||
| Net cash paid for acquisitions and acquisition costs | ||
| Contingent consideration obligations | ||
| Acquisition From Bayer | ||
| Total contingent consideration obligations | ||
| Fair value of assets acquired | ||
| Acquisition From Bayer | ||
| Total fair value of assets acquired | ||
| Accrual for dissenting shares | ||
| Acquired in-process research and development | ||
| Gain on acquisition of business | ||
| Net liabilities assumed |
Loading...
